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Abstract
Aims
Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines rec-
ommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke preven-
tion in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-
treated patients with newly diagnosed AF in the ongoing, global, observational registry
GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we ana-
lysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE),
major bleeding, and all-cause mortality.
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Methods and Results
TTR was calculated for 9934 patients using 136,082 INR measurements during 1-year fol-
low-up. The mean TTR was 55.0%; values were similar for different VKAs. 5851 (58.9%)
patients had TTR<65%; 4083 (41.1%) TTR65%. The proportion of patients with
TTR65% varied from 16.7% in Asia to 49.4% in Europe. There was a 2.6-fold increase in
the risk of stroke/SE, 1.5-fold increase in the risk of major bleeding, and 2.4-fold increase in
the risk of all-cause mortality with TTR<65% versus65% after adjusting for potential con-
founders. The population attributable fraction, i.e. the proportion of events attributable to
suboptimal anticoagulation among VKA users, was 47.7% for stroke/SE, 16.7% for major
bleeding, and 45.4% for all-cause mortality. In patients with TTR<65%, the risk of first
stroke/SE was highest in the first 4 months and decreased thereafter (test for trend, p =
0.021). In these patients, the risk of first major bleed declined during follow-up (p = 0.005),
whereas in patients with TTR65%, the risk increased over time (p = 0.027).
Conclusion
A large proportion of patients with AF had poor VKA control and these patients had higher
risks of stroke/SE, major bleeding, and all-cause mortality. Our data suggest that there is
room for improvement of VKA control in routine clinical practice and that this could substan-
tially reduce adverse outcomes.
Trial Registration
ClinicalTrials.gov NCT01090362
Introduction
Vitamin K antagonists (VKAs) had been the only recommended anticoagulants for stroke pre-
vention in patients with atrial fibrillation (AF) before non-vitamin K antagonist oral anticoagu-
lants (NOACs) were developed for this indication [1]. Despite the beneficial benefit/risk ratio
of NOACs, VKAs have remained a frequently used therapy in clinical routine. The Global
Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) is an observational
study of patients newly diagnosedwith non-valvular AF evaluating the management of these
patients in clinical routine worldwide [2]. The registry started in 2009, at the end of the VKA-
only era, providing insights into changes in treatment patterns over time.
An analysis of the first 10,614 patients included in the GARFIELD-AF registry has shown
that the patients’ stroke risk profile does not always match the prescribing pattern of anticoagu-
lants [3]. The 2013 publication describes the baseline characteristics and initial therapeutic
management of patients with non-valvular AF, with and without antithrombotic treatment,
and indicates that anticoagulant drugs are frequently not being used according to stroke risk
scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of
stroke. This is a crucial finding for the use of VKAs since these anticoagulants have a narrow
therapeutic window and need to be individually dosed based on international normalised ratio
(INR) control. According to international guidelines, the optimal INR range to minimise
ischaemic stroke and bleeding is between 2.0–3.0 [4, 5]. Various methods are used to describe
the quality of INR control, e.g., proportion of time in therapeutic range (TTR), frequency in
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therapeutic range (FIR), and levels of anticoagulation in narrow INR bands of 0.5. Recently, we
showed that TTR and FIR are not equivalent and should not be used interchangeably [6]. Our
earlier analyses also suggested that TTRmay be preferable to FIR because it takes into account
the time between INR readings. However, both methods refer to a predefined target range of
INR and so information about over- or underanticoagulation is not obtained.
In this paper, we analyse the TTR of VKA-treated patients enrolled prospectively in the
GARFIELD-AF registry and analyse the relationship betweenTTR and 1-year outcomes
(stroke/systemic embolism [SE], major bleeding, and all-causemortality).
Methods
Study design
GARFIELD-AF is a worldwide observational prospective registry of adults with newly diag-
nosed non-valvular AF [2]. Women and men aged18 years with a diagnosis of non-valvular
AF within the past 6 weeks and at least one additional investigator-defined risk factor for stroke
are eligible for enrolment, regardless of therapy. Patients with a transient reversible cause of AF
and those for whom follow-up is unlikely are excluded. Patients are enrolled from 2010 to
2016.
This paper reports 1-year follow-up data for prospective patients enrolled fromMay 2010
to September 2015 treated with VKA (with or without antiplatelet therapy). The data were
extracted from the study database on 28 July 2016.
Ethics statement
All patients provided written informed consent to participate. Independent ethics committee
and hospital-based institutional review board approvals were obtained, as necessary, for the
registry protocol. A list of central ethics committees and regulatory authorities that provided
approval can be found in S2 File. Additional approvals were obtained from individual study
sites. The registry is being conducted in accordance with the principles of the Declaration of
Helsinki, local regulatory requirements, and the International Conference on Harmonisation-
GoodPharmacoepidemiological and Clinical Practice Guidelines.
Data collection
Data were collected using an electronic case report form (eCRF) and captured by trained per-
sonnel. The eCRFwas designed by Dendrite Clinical Systems Ltd, Henley-on-Thames, UK,
which is also responsible for ongoing database programmanagement. Outcome events were
reported by investigators, after review of patient notes and clinical records, and audited using a
combination of remote electronicmonitoring and more conventional onsite monitoring
(including source data verification on 20% of cases) [2].
Statistical analysis
INR readings and TTR. INR readings during the first year of follow-up were included in
the analysis. TTRwas estimated between two consecutive INR readings only if the interval did
not exceed 90 days. Implausible INR values of less than 0.8 or greater than 20 were excluded.
Patients on VKA treatment at enrolment, but with fewer than three readings during the fol-
low-up, were excluded from the analysis. Patient-level TTRwas estimated by linear interpola-
tion according to Rosendaal et al. [7], using 2.0–3.0 as the target INR range. TTRwas estimated
using INR readings until discontinuation or interruption of VKA, an outcome event, or the
end of follow-up. Thus, INR values after a stroke/SE were not used to study the relationship
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betweenTTR and stroke/SE, and INR values after a major bleed were not used to study the
relationship between TTR and major bleeding.
Baseline patient characteristics. Baseline patient characteristics were analysed for the
total population and by level of TTR, using the cut-off of 65%. TTR<65% has been defined by
the UKNational Institute for Health and Care Excellence (NICE) to indicate poor VKA control
[8]. Counts and percentages are reported for categorical variables; means and standard devia-
tions (SDs) are reported for continuous variables.
TTR by type of VKA and by concomitant antiplatelet therapy. The types of VKA (war-
farin, acenocoumarol, phenprocoumon and other) received by patients at enrolment are col-
lected. For the category of ‘other’ VKA therapies, the drug names are not collected. The types
of VKA are reported as counts and percentages. Mean, SD, median, and interquartile range
(IQR) were estimated to describe the distribution of TTR by type of VKA and by concomitant
antiplatelet therapy.
Distribution of INR values. The distribution of INR values is describedby counts and
percentages below, within, and above the therapeutic range, and by the mean, SD, median, and
IQR.
Clinical outcomes. Stroke/SE, major bleeding, and all-causemortality events occurring
during the first year of follow-up are describedusing the number of events, the population at
risk at the beginning of the follow-up period, and rate. Only the first occurrence of each event
was taken into account. Haemorrhagic strokes were counted as a major bleed event and as a
stroke event. Person-time event rates (per 100 person-years) by the TTR cut-off of 65% were
estimated using a Poisson model with the number of events as the dependent variable and the
log of person-time as an offset.
Hazard ratios (HRs) were estimated for TTR<65% vs TTR65% (reference group) using a
Coxmodel. The proportional hazards assumption was assessed visually using a plot of the sur-
vivor function over time by TTR level. HRs were controlled for the following potential con-
founders: age group (64, 65–69, 70–74,75 years), gender, smoking (no, ex, current),
congestive heart failure, vascular disease,moderate-to-severe chronic kidney disease, diabetes
mellitus, hypertension, previous stroke (not included in the model for major bleeding events),
previous bleeding (not included in the model for stroke/SE), antiplatelet treatment, type of AF,
and area (Europe, Asia, other countries).
A patient may be classified in different groups (TTR65% or TTR<65%) for different clini-
cal outcomes, since INR readings after the event were not included when estimating TTR.
Strokes occurring after a major bleed were included in the analysis of strokes; major bleeds
after a stroke event were included in the analysis of major bleeding; and deaths after a stroke or
major bleed were included in the mortality analysis. The estimation of TTRwas censored when
there was an interruption of VKA treatment; however, the time to event in the Cox model was
not censored for an interruption of VKA treatment.
The incidence rates described above were analysed by 4-month intervals as well. The overall
TTR values used in the main analyses were also used to define the TTR group for each
4-month interval. The 4-month rates of events were compared with the overall rates using the
ratio between the observednumber of events in the period and the expected number of events
obtained by applying the overall rate to the period. The Poisson trend statistic was used to
assess the trends over time.
Sensitivity analysis. Estimation of TTR and analysis of outcomes were repeated, excluding
INR readings and events during the first 3 months of treatment for patients with three or more
readings during the last 9 months.
Missing values. In descriptive statistics, for a single variable we excluded all patients for
which the variable was missing (available-case analysis). HRs were estimated using a
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proportional hazards Coxmodel after multiple imputation by the Multiple Imputation by
Chained Equations (MICE) algorithm.
Statistical software. Analyses were double performed using SAS, release 9.4 (SAS Insti-
tute, Cary, NC, USA) and Stata, version 14 (StataCorp, College Station, TX, USA).
Results
Baseline patient characteristics
In total, 39,898 patients were enrolled in GARFIELD-AF. Of the 39,368 patients with data on
antithrombotic treatment at baseline, 16,852 (42.8%) were treated with VKAs (with or without
antiplatelet therapy). Among the VKA-treated patients, 6440 (38.2%) had<3 INR readings
and were excluded from the analysis. Of the 10,412 remaining patients, 478 (4.6%) who had
INR readings with a gap of>90 days were excluded, leaving 9934 patients (58.9% of VKA-
treated patients) who had at least three INR readings with an interval not exceeding 90 days,
with a total of 136,082 INRmeasurements. Among the patients included in the analysis, 82.1%
had 6+ INR readings. The number of patients enrolled in each of the 35 countries participating
in GARFIELD-AF is shown in S1 Table.
Using INR 2.0–3.0 as the target range, 5851 patients (58.9%) had a TTR of<65% and 4083
patients (41.1%) had a TTR of65%. Baseline characteristics of the overall population and
according to TTR level (<65% vs65%) are shown in Table 1. A greater proportion of the
TTR<65% group had a bodymass index (BMI) of<25 kg/m2 compared with the TTR65%
group (32.6% vs 25.9%). Conversely, a greater proportion of the TTR65% group had a BMI
of 30–<40 kg/m2 (31.0% vs 26.4% for the<65% group). The proportion of patients with
TTR65% varied from 16.7% in Asia to 49.4% in Europe (Table 2).
VKA control
Overall, the mean (SD) INR was 2.4 (0.9) and the median (IQR) was 2.3 (1.8 to 2.8). Of the
total INR values, 51.4% were in the therapeutic range of 2.0–3.0, 32.1% were below, and 16.5%
were above this range.
Warfarin was the most frequently used VKA at enrolment (66.7% of patients), followed by
acenocoumarol (24.0% of patients; Table 3). Of the patients receiving ‘other’ VKA therapy, the
majority were from France (191/231, 82.7%), where published reports indicate that fluindione
is the most frequently used VKA [9]. The mean TTR for the total study group was 55.0%. The
mean TTR for patients receiving warfarin was 55.4% (median: 60.8%). Patients on acenocou-
marol at enrolment had the lowest TTR (mean: 52.9%; median: 54.7%). The mean TTRwas
similar for patients on VKA only and for those on VKA with antiplatelet therapy (Table 4).
The mean TTR values were<65% for all types of VKA regardless of whether patients received
concomitant antiplatelet therapy.
Clinical outcomes
The rate of stroke/SE during 1-year follow-up was 1.46 (95% confidence interval [CI] 1.18 to
1.82) per 100 person-years for patients with TTR<65% and 0.65 (0.44 to 0.96) per 100 person-
years for patients with TTR65% (Fig 1). The rate of major bleeding was 1.52 (1.23 to 1.88)
per 100 person-years for patients with TTR<65% and 0.93 (0.67 to 1.28) per 100 person-years
for patients with TTR65% (Fig 1). The rate of all-cause mortality was 4.59 (4.06 to 5.18) per
100 person-years for patients with TTR<65% and 2.22 (1.80 to 2.73) per 100 person-years for
patients with TTR65% (Fig 1). For the first major bleeding events, 14 (11.5%) were followed
by a first stroke.
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Table 1. Baseline characteristics of patients according to proportion of time in therapeutic range.
TTR<65% (N = 5851; 58.9%) TTR65% (N = 4083; 41.1%) Total (N = 9934; 100%)
Age, mean (SD), years 70.7 (10.6) 71.9 (9.7) 71.2 (10.2)
Age group, n/N, %
65–74 years 2029/5851 34.7 1430/4083 35.0 3459/9934 34.8
75 years 2343/5851 40.0 1786/4083 43.7 4129/9934 41.6
Women, n/N, % 2649/5851 45.3 1791/4083 43.9 4440/9934 44.7
BMI category, n/N, %
<19 kg/m2 109/4594 2.4 40/3137 1.3 149/7731 1.9
19–<25 kg/m2 1390/4594 30.3 771/3137 24.6 2161/7731 28.0
25–<30 kg/m2 1715/4594 37.3 1245/3137 39.7 2960/7731 38.3
30–<40 kg/m2 1214/4594 26.4 973/3137 31.0 2187/7731 28.3
40 kg/m2 166/4594 3.6 108/3137 3.4 274/7731 3.5
Medical history, n/N, %
Congestive heart failure 1189/5851 20.3 673/4083 16.5 1862/9934 18.7
History of hypertension 4574/5842 78.3 3283/4073 80.6 7857/9915 79.2
Diabetes mellitus 1490/5851 25.5 888/4083 21.7 2378/9934 23.9
Prior stroke/transient ischaemic attack 751/5851 12.8 583/4083 14.3 1334/9934 13.4
Vascular disease* 814/5842 13.9 608/4077 14.9 1422/9919 14.3
Chronic kidney disease (Grade3)† 749/5851 12.8 522/4083 12.8 1271/9934 12.8
History of bleeding 121/5838 2.1 70/4077 1.7 191/9915 1.9
Alcohol consumption, n/N, %
Abstinent 2585/4943 52.3 1544/3346 46.1 4129/8289 49.8
Light 1701/4943 34.4 1427/3346 42.6 3128/8289 37.7
Moderate 521/4943 10.5 323/3346 9.7 844/8289 10.2
Heavy 136/4943 2.8 52/3346 1.6 188/8289 2.3
Smoker, n/N, %
No 3329/5277 63.1 2332/3671 63.5 5661/8948 63.3
Ex-smoker 1411/5277 26.7 1055/3671 28.7 2466/8948 27.6
Current smoker 537/5277 10.2 284/3671 7.7 821/8948 9.2
*Peripheral artery disease or coronary artery disease with a history of acute coronary syndromes.
†Renal function was assessed according to the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative classification by investigators at
baseline.
BMI, body mass index; SD, standard deviation; TTR, time in therapeutic range.
doi:10.1371/journal.pone.0164076.t001
Table 2. Proportion of patients with TTR <65% and65% in different geographic regions.
TTR<65% (n/N, %) TTR65% (n/N, %)
Europe 3462/6840 50.6 3378/6840 49.4
North America 119/220 54.1 101/220 45.9
Latin America 461/588 78.4 127/588 21.6
Asia 1581/1899 83.3 318/1899 16.7
Rest of the world 228/387 58.9 159/387 41.1
TTR, time in therapeutic range.
Europe: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy,
Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Ukraine, UK; North America: Canada,
USA; Latin America: Argentina, Brazil, Chile, Mexico; Asia: China, India, Japan, Korea, Singapore, Thailand,
Turkey, UAE; rest of the world: Australia, Egypt, South Africa.
doi:10.1371/journal.pone.0164076.t002
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HRs showed a 2.6-fold increase in the risk of stroke/SE with a TTR of<65% compared with
65% (Fig 1 and Table 5). TTR of<65% was also associated with a 1.5-fold increase in the risk
of major bleeding and a 2.4-fold increase in the risk of all-causemortality. The population
attributable fraction, i.e. the proportion of events attributable to suboptimal anticoagulation
among VKA users, was 47.7% for stroke/SE, 16.7% for major bleeding, and 45.4% for all-cause
mortality. The sensitivity analysis, excluding INR readings and events during the first 3 months
of treatment, showed that the increased risks of stroke/SE, major bleeding and all-causemortal-
ity associated with TTR<65% prevailed (Table 5).
The risk of the first stroke/SE during this follow-up periodwas highest in the first 4 months
of follow-up and decreased over time in patients with TTR<65%, whereas no change in risk of
stroke/SE was seen in patients with TTR65% over time (Table 6, Fig 2A and S2 Table; test for
trend, TTR<65% p = 0.021, TTR65% p = 0.999, overall p = 0.045). The types of stroke are
listed in S3 Table, which shows that the risk of stroke in the first 4 months was clearly domi-
nated by ischaemic events in patients with TTR<65%, whereas the number of haemorrhagic
strokes did not change over time regardless of whether TTRwas<65% or65%. The risk of
first major bleed declined over time in patients with TTR<65%, while it increased in patients
with TTR65% (Table 6, Fig 2B and S2 Table; test for trend, TTR<65% p = 0.005, TTR65%
p = 0.027). Overall, the risk of first major bleed in all patients did not show a trend during the
follow-up period (Table 6 and S2 Table; test for trend, p = 0.267). The risk of all-cause mortal-
ity during the follow-up period increased in patients with TTR<65% and in those with
TTR65% (Table 6, Fig 2C and S2 Table; test for trend, TTR<65% p = 0.047, TTR65%
p = 0.027, overall p = 0.005).
Discussion
Contemporary, observational, worldwide data from 10,614 patients in the GARFIELD-AF reg-
istry, enrolled from 2009 to 2011 in 19 countries, have shown that anticoagulants are often
overused in patients at low risk and underused in those at high risk of stroke [3]. VKAs remain
a commonly prescribed anticoagulant therapy in patients with AF, even after the introduction
of NOACs. This paper is the first publication of GARFIELD-AF analysing outcomes related to
quality of VKA control. The analysis includes 9934 VKA-treated patients with at least three
Table 3. Proportion of time in therapeutic range (%) for patients on different vitamin K antagonists*.
VKA therapy n (%) Mean SD Median Interquartile range
Warfarin 6513 (66.7) 55.4 28.4 60.8 35.7 to 77.6
Acenocoumarol 2345 (24.0) 52.9 23.7 54.7 37.4 to 70.4
Phenprocoumon 672 (6.9) 56.2 26.7 57.6 37.3 to 77.3
Other 231 (2.4) 59.2 28.1 65.6 38.9 to 80.4
*N = 9934; data missing for 173 patients.
SD, standard deviation; VKA, vitamin K antagonist.
doi:10.1371/journal.pone.0164076.t003
Table 4. Proportion of time in therapeutic range (%) for patients on vitamin K antagonists with and without concomitant antiplatelet therapy.
Therapy n (%) Mean SD Median Interquartile range
VKA 7752 (78.0) 55.5 27.1 59.4 37.6 to 76.0
VKA+AP 2182 (22.0) 53.3 27.9 56.7 33.4 to 75.3
AP, antiplatelet; SD, standard deviation; VKA, vitamin K antagonist.
doi:10.1371/journal.pone.0164076.t004
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INR readings, out of a total of 39,898 patients recruited in GARFIELD-AF from 2010 to 2015
in 35 countries. All patients had newly diagnosednon-valvular AF and were followed up for 1
year.
European and American guidelines for stroke prevention in AF recommend an INR range
of 2.0–3.0 for patients treated with VKA [4, 5], although country- and region-specific guidance
may differ. The Japanese Circulation Society recommends an INR of 2.0–3.0 for all patients
with AF except those aged70 years, for whom 1.6–2.6 is recommended [10], which is sup-
ported by the Asia Pacific Heart Rhythm Society statement on antithrombotic therapy of
patients with non-valvular AF [11]. The Federation of Dutch Thrombosis Services,until
recently, defined the target INR range of 2.5–3.5 and the therapeutic range of 2.0–3.5 [12]. For
the purposes of these analyses, we applied the target INR range of 2.0–3.0 and a cut-off TTR of
65% as the measure of the quality of patient management. In international guidelines, the cut-
Fig 1. Incidence rates and adjusted hazard ratios for 1-year clinical outcomes according to proportion of
time in therapeutic range. Reference group: TTR65%. Incidence rates are per 100 person-years. CI,
confidence interval; HR, hazard ratio; SE, systemic embolism; TTR, time in therapeutic range. HRs were
controlled for the following potential confounders: age group (64, 65–69, 70–74,75 years), gender, smoking
(no, ex, current), congestive heart failure, vascular disease, moderate-to-severe chronic kidney disease, diabetes
mellitus, hypertension, previous stroke (not included in the model for major bleeding events), previous bleeding
(not included in the model for stroke/SE), antiplatelet treatment, type of atrial fibrillation, and area (Europe, Asia,
other countries).
doi:10.1371/journal.pone.0164076.g001
Table 5. Adjusted hazard ratios for 1-year clinical outcomes by proportion of time in therapeutic range for the main analysis and sensitivity anal-
ysis (excluding international normalised ratio readings and events during the first 3 months of treatment).
Main analysis Sensitivity analysis
Population at risk (N) Events HR 95% CI Population at risk (N) Events HR 95% CI
Stroke/SE TTR65% 4080 26 1 - 3967 24 1 -
TTR<65% 5844 82 2.55 1.61 to 4.03 4211 48 2.35 1.38 to 4.00
Major bleeding TTR65% 4081 37 1 - 3974 43 1 -
TTR<65% 5842 85 1.54 1.04 to 2.26 4206 45 1.31 0.83 to 2.06
All-cause mortality TTR65% 4083 89 1 - 3968 63 1 -
TTR<65% 5851 259 2.39 1.87 to 3.06 4218 132 2.27 1.74 to 2.97
CI, confidence interval; HR, hazard ratio; SE, systemic embolism; TTR, time in therapeutic range.
HRs were controlled for the following potential confounders: age group (64, 65–69, 70–74,75 years), gender, smoking (no, ex, current), congestive
heart failure, vascular disease, moderate-to-severe chronic kidney disease, diabetes mellitus, hypertension, previous stroke (not included in the model for
major bleeding events), previous bleeding (not included in the model for stroke/SE), antiplatelet treatment, type of atrial fibrillation, and area (Europe, Asia,
other countries).
doi:10.1371/journal.pone.0164076.t005
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off of TTR varies between 60% and 70% [4, 10, 11], and NICE uses TTR of less than 65% as an
indicator for poor control [8].
Real-world data from our study indicate that a TTR target of at least 65% is often not
achieved in routine clinical practice, regardless of the type of VKA. For all VKAs used in GAR-
FIELD-AF including warfarin, acenocoumarol, phenprocoumon, and others, the mean TTR
values were below 65%. In addition, we observedmarked regional variations in TTR,with the
proportion of patients with TTR65% varying from 16.7% in Asia to 49.4% in Europe. The
low proportion of patients with TTR65% in Asia is consistent with a previous analysis from
GARFIELD-AF showing that patients in Asia had lower INR values than those in other regions
of the world [13]. It may be that physicians in Asia target a lower INR than those in other
regions (as per the Asia Pacific Heart Rhythm Society guidelines for patients aged70 years
[11]). Our analysis also showed that patients in Asia had a lower frequency of INR
measurements.
Since TTR does not provide information about over- or underanticoagulation, additional
information in this regard can be obtained by the percentages of INR values within, below, or
above the target range of 2.0–3.0. Only 51.4% of all INR values measured were within range,
whereas 32.1% were below and 16.5% above this range. Thus, underanticoagulation is more
frequent than overanticoagulation in this global registry. This confirms the conclusion from a
previous meta-analysis and meta-regression on quality of VKA control and outcomes in
patients with AF where patients on VKA were frequently outside the target INR range and
tended to be underanticoagulated rather than overanticoagulated [14].
As shown in S3 Table, there was a clear predominance of primary ischaemic strokes over
primary intracerebral haemorrhages in both TTR groups, although this was much more
Table 6. Four-month event rates in patients with proportion of time in therapeutic range <65% and65%.
TTR<65% TTR65% Total
Events Rate, per 100 person-years
(95% CI)
Events Rate, per 100 person-years
(95% CI)
Events Rate, per 100 person-years
(95% CI)
Stroke/SE 1st to 4th
months
36 1.88 (1.35 to 2.60) 8 0.59 (0.30 to 1.19) 44 1.35 (1.00 to 1.81)
5th to 8th
months
29 1.54 (1.07 to 2.22) 10 0.75 (0.40 to 1.39) 39 1.21 (0.89 to 1.66)
9th to 12th
months
17 0.94 (0.59 to 1.52) 8 0.61 (0.31 to 1.22) 25 0.80 (0.54 to 1.19)
Total 82 1.46 (1.18 to 1.82) 26 0.65 (0.44 to 0.96) 108 1.13 (0.93 to 1.36)
Major bleeding 1st to 4th
months
39 2.03 (1.49 to 2.78) 11 0.82 (0.45 to 1.48) 50 1.53 (1.16 to 2.02)
5th to 8th
months
30 1.60 (1.12 to 2.28) 4 0.30 (0.11 to 0.80) 34 1.06 (0.76 to 1.48)
9th to 12th
months
16 0.89 (0.54 to 1.45) 22 1.68 (1.11 to 2.56) 38 1.22 (0.89 to 1.68)
Total 85 1.52 (1.23 to 1.88) 37 0.93 (0.67 to 1.28) 122 1.27 (1.07 to 1.52)
All-cause
mortality
1st to 4th
months
74 3.84 (3.06 to 4.83) 22 1.63 (1.07 to 2.47) 96 2.93 (2.40 to 3.58)
5th to 8th
months
89 4.70 (3.82 to 5.78) 29 2.16 (1.50 to 3.11) 118 3.64 (3.04 to 4.36)
9th to 12th
months
96 5.27 (4.31 to 6.43) 38 2.89 (2.11 to 3.97) 134 4.27 (3.61 to 5.06)
Total 259 4.59 (4.06 to 5.18) 89 2.22 (1.80 to 2.73) 348 3.61 (3.25 to 4.01)
CI, confidence interval; SE, systemic embolism; TTR, time in therapeutic range.
doi:10.1371/journal.pone.0164076.t006
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Fig 2. Four-month rate ratios by proportion of time in therapeutic range for (A) stroke/systemic embolism, (B) major bleeding,
and (C) all-cause mortality. SE, systemic embolism; TTR, time in therapeutic range.
doi:10.1371/journal.pone.0164076.g002
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pronounced in patients with TTR<65%. Suboptimal anticoagulation control determined by
TTR<65%was associated with a predominance of ischaemic stroke events, especially in the
first 4 months of follow-up. When all types of stroke were taken together, an increased risk of
1-year stroke/SE was observedwith TTR<65%, compared with TTR65%. This trend was also
apparent for major bleeding, and all-cause mortality, as shown in Fig 1. In our study, the popu-
lation attributable fraction, i.e. the proportion of events attributable to suboptimal anticoagula-
tion among VKA users, was 47.7% for stroke/SE, 16.7% for major bleeding, and 45.4% for all-
cause mortality. An advantage of our analyses is that they reflect the use of VKAs in real life,
where VKA treatment in patients with AF usually is not initiated with overlapping treatment
with heparin to overcome the prothrombotic activity of VKA in the initial treatment period.
Putting these results into perspective, it is apparent from the literature that optimisation of
VKA control has not improved over time. Hylek et al. [15] analysed the lowest effective inten-
sity of prophylactic anticoagulation for patients with nonrheumatic AF and stated that tight
control of anticoagulant therapy to maintain the INR between 2.0 and 3.0 is a better strategy
than targeting lower, less effective levels of anticoagulation.More recently, Gallagher et al. [16]
in a retrospective study of the medical records from 37,907 patients with AF from the UK Gen-
eral Practice Research Database found that TTRwas a strong predictor of stroke. Another ret-
rospective study based on Swedish registries, especially AuriculA, a quality register for AF and
oral anticoagulation, was recently published [17]. In total, 40,449 patients with non-valvular
AF started on warfarin were monitored until treatment cessation, death, or the end of the
study. The authors concluded that well-managed warfarin therapy is associated with a low risk
of complications and is still a valid alternative for prophylaxis of AF-associated stroke. They
also emphasised that individual TTR is a strong indicator of probability for both bleeding and
thromboembolic events and should be maintained at 70% or greater.
Since all of these analyses were conducted in non-Asian countries, future analyses will need
to show whether the target INR range of 2.0–3.0 can also be used generally for Asian patients
to optimise clinical outcome.
As GARFIELD-AF enrols newly diagnosed patients with non-valvular AF, an additional
analysis of 4-month rate ratios by TTR for stroke/SE, major bleeding, and all-causemortality
was performed to have a special focus on the initial treatment phase, which is the most critical
phase for patients treated with VKA due to the potential prothrombotic effects of these drugs
in the early period of therapy [18]. In patients with TTR<65%, the highest rate ratios of stroke/
SE and major bleedingwere observedduring the first 4 months after enrolment and the rates
declined in the second and third 4-month periods. Conversely, in patients with TTR65% the
risk of stroke/SE did not show a trend over time but the risk of major bleedingwas highest in
the third 4-month period. The latter finding confirms a previous publication reporting an
increase of bleeding over time in patients with venous thromboembolismwho are anticoagu-
lated with VKA [19]. The authors compared major bleeding in patients with prolonged and
short treatment and found major bleeding rates of 2.4% and 0.9%, respectively. They concluded
that their analysis of pooled data showed an increase in major bleeding during the entire study
period (risk ratio 2.609, 95% CI 1.51 to 4.49, p = 0.0006). The risk of all-causemortality
increased over time in patients with TTR65%. This may be due to reasons not related to
anticoagulation therapy and will be explored in more detail in future analyses of GARFIEL-
D-AF, after outcome data of all cohorts have become available. As shown in the listing of the
corresponding types of stroke in S3 Table, there was an accumulation of ischaemic stroke
events for the TTR<65% group during the first 4 months of treatment, whereas the number of
haemorrhagic strokes remained unchanged over time, i.e. three events in each 4-month period.
Whether this can be attributed to the vulnerable phase of the initiation of VKA, or to patient-
related factors, cannot be concluded at the present time and needs further exploration after the
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termination of this global registry, when the outcome results of all VKA patients from GAR-
FIELD-AF become available. However, these 4-month analyses are in line with the findings of
Azoulay et al. [18] that patients initiating warfarin are at an increased risk of stroke during the
early period of treatment, supporting the hypothesis that warfarin may induce a transient
hypercoagulable state at the start of treatment. Additional studies are needed to confirm these
findings.
Our analyses confirmed that poor VKA control correlates with poor clinical outcomes—
and this finding is applicable in global patient populations treated under the conditions of dif-
ferent health care systems, although the target INR range of 2.0–3.0 has not been unanimously
recommended in all regions and countries participating in GARFIELD-AF. A limitation of this
analysis is that TTRwas used as a proxy for the quality of patient management. It is a time-
dependent variable but it was used as if it was constant over time. Thus, our findings cannot be
used to inform patient prognosis nor treatment decisions regarding anticoagulation for indi-
viduals with AF [20]. Although the SAMe-TT2R2 score is helpful in predicting the probability
of anticoagulation control with VKAs and clinical outcomes, such studies have only been per-
formed for homogeneous patient populations from single countries [21–24]. These are mainly
retrospective [23, 24], single-centre [21, 23, 24] studies, one of which included only patients
who were stable on acenocoumarol, with high initial TTR at study entry [21].
In this analysis, the mortality rate was not high; more patients died than had either first
stroke/SE or major bleed events. This competing risk of outcomes could have affected the
cause-specific rates for stroke/SE and major bleeding, especially in the latter two 4-month
intervals. The event rates for these same outcomes were low, especially in the subgroup of
patients with TTR65%within each 4-month period. Furthermore, there is potential bias in
the analysis from the fact that poor TTR is more likely in the presence of concurrent illnesses
or procedures (not requiring VKA interruption) that could expose the patient to adverse out-
comes, in addition to a poor TTR.
Among the strengths of this paper is that, in contrast to many previous publications on out-
comes in patients with AF treated with VKAs, GARFIELD-AF is a global registry reflecting
routine clinical practice worldwide, across various health care systems and settings. This is also
the first publication of TTR data from a global registry of newly diagnosed patients with AF
that reports on a wide range of VKAs, including warfarin, phenprocoumon, acenocoumarol,
and others. Furthermore, the data are prospectively collected and potential change of patient
care can be timely assessed in the near future.
Conclusions
These contemporary analyses of VKA control and outcomes in GARFIELD-AF show that
patients with poor VKA control have higher risks of stroke/SE, major bleeding, and all-cause
mortality than patients with good control, which suggests that overall meticulousVKAmanage-
ment would potentially lead to fewer adverse outcomes. In patients with poor VKA control, the
risks of stroke/SE and major bleeding are highest in the first 4 months of treatment. The data also
show that the optimal management of VKA for stroke prevention is still a challenge in routine
clinical practice. Despite the plethora of publications emphasising the necessity of laboratory-
controlled dosing using predefined INR target ranges and the use of VKA for many decades, con-
tinuing educational activities are needed to improve stroke prevention in patients with AF.
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